Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Sept. 4, 2024
Language: Английский
MMWR Morbidity and Mortality Weekly Report, Journal Year: 2024, Volume and Issue: 73(4), P. 77 - 83
Published: Feb. 1, 2024
On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to prevent COVID-19, including severe disease. During fall XBB lineages co-circulated JN.1, an Omicron BA.2.86 lineage that emerged in 2023. These variants have amino acid substitutions might increase escape from neutralizing antibodies. predominated through December when JN.1 became predominant the United States. Reduction or failure of spike gene (S-gene) amplification (i.e., S-gene target [SGTF]) real-time reverse transcription-polymerase chain reaction testing is time-dependent, proxy indicator infection. Data Increasing Community Access Testing SARS-CoV-2 pharmacy program were analyzed estimate effectiveness (VE) receipt versus no vaccination) against symptomatic infection, by SGTF result. Among 9,222 total eligible tests, overall VE among adults ≥18 years was 54% (95% CI = 46%-60%) at median 52 days after vaccination. 2,199 tests performed laboratory testing, 60-119 49% 19%-68%) exhibiting and 60% 35%-75%) without SGTF. Updated vaccines provide protection currently circulating lineages. CDC will continue monitoring VE, expected waning All should receive dose.
Language: Английский
Citations
106
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(7), P. e416 - e416
Published: May 20, 2024
Language: Английский
Citations
60
Eurosurveillance, Journal Year: 2024, Volume and Issue: 29(2)
Published: Jan. 11, 2024
Variant BA.2.86 and its descendant, JN.1, of SARS-CoV-2 are rising in incidence across Europe globally. We isolated recent BA.2.86, EG.5, XBB.1.5 earlier variants. tested live virus neutralisation sera taken September 2023 from vaccinated exposed healthy persons (n = 39). found clear escape against variants but no specific pronounced for or JN.1. Neutralisation corresponds to variant predominance may not be causative the upsurge JN.1 incidence.
Language: Английский
Citations
56
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(8), P. e482 - e483
Published: June 27, 2024
The SARS-CoV-2 JN.1 variant (BA.2.86.1.1), arising from BA.2.86.1 with spike-protein substitution Leu455Ser, had outcompeted the previously predominant XBB lineages by beginning of 2024.1Kaku Y Okumura K Padilla-Blanco M et al.Virological characteristics variant.Lancet Infect Dis. 2024; 24: e82Summary Full Text PDF PubMed Google Scholar Subsequently, subvariants, including KP.2 (JN.1.11.1.2) and KP.3 (JN.1.11.1.3), which acquired additional substitutions (eg, Arg346Thr, Phe456Leu, Gln493Glu), have emerged concurrently (appendix pp 12–13).2Kaku Uriu Kosugi (published online May 20.)https://doi.org/10.1016/S1473-3099(24)00298-6Summary Scopus (0) Furthermore, subvariants such as LB.1 (JN.1.9.2.1) KP.2.3 (JN.1.11.1.2·3), convergently a deletion at 31st position in S (Ser31del) addition to aforementioned substitutions, spread June, 2024 12–13). In May, 2024, we reported virological features KP.2;2Kaku this Correspondence, investigate properties KP.3, LB.1, KP.2.3. We estimated relative effective reproduction number (Re) using Bayesian multinomial logistic model3Yamasoba D Kimura I Nasser H omicron BA.2 spike.Cell. 2022; 185: 2103-2115Summary (190) based on genome surveillance data Canada, UK, USA, where these variants 9–13). Re was more than 1·2-fold higher that or similar countries Notably, values were those These results suggest three investigated will worldwide, KP.2.2Kaku then conducted immunological experiments pseudoviruses. pseudovirus infectivity human HOS-ACE2/TMPRSS2 cells significantly lower Conversely, Neutralisation assay convalescent serum samples after breakthrough infection XBB.1.5 EG.5, vaccination status-unknown HK.3 JN.1, monovalent vaccination. all four groups tested, 50% neutralisation titres against (2·2-fold 3·3-fold 2·0-fold 2·9-fold) even (1·6-fold 1·9-fold 1·4-fold 1·7-fold; appendix Although showed resistance tested 2·2-fold) statistical significance, there no significant differences between infection-naive vaccine samples, titre very low For natural infection, (2·1-fold 2·8-fold) (1·4-fold 2·0-fold; Overall, increased immune evasion compared parental JN.1. Moreover, Ser31del, robust KP.2. Ser31del is crucial for infectivity, enhanced evasion, Re. Continuously monitoring assessing effects across various proteins are necessary future studies. KS supported AMED Strategic Center Biomedical Advanced Vaccine Research Development Preparedness Response (SCARDA) Initiative World-leading Centers (JP243fa627001h0003); SCARDA programme research development new generation vaccine, modality application (JP243fa727002); Program Emerging Re-emerging Infectious Diseases (JP24fk0108690); JSPS KAKENHI Grant-in-Aid Scientific A (JP24H00607); Cooperative (Joint Usage/Research programme) Institute Life Medical Sciences Kyoto University (Kyoto, Japan); receives consulting fees Moderna Japan Takeda Pharmaceutical; honoraria lectures Shionogi. JI Science Technology Agency PRESTO (JPMJPR22R1) Early-Career Scientists (JP23K14526) Pharmaceutical. Mitsubishi United Financial Group Grant. MSY Japanese Government Ministry Education, Culture, Sports, Scholarship–Research Category (240042). JET (220235). Genotype Phenotype Consortium supported, part, (AMED) Adopting Sustainable Partnerships Innovative Ecosystem (JP24jf0126002) Society Promotion (JSPS) Fund Joint International (JP23K20041). All other authors declare competing interests. Download .pdf (.64 MB) Help pdf files Supplementary
Language: Английский
Citations
51
Trends in Immunology, Journal Year: 2024, Volume and Issue: 45(2), P. 81 - 84
Published: Jan. 31, 2024
Language: Английский
Citations
36
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(10), P. e609 - e609
Published: Aug. 16, 2024
Language: Английский
Citations
36
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(9), P. 964 - 973
Published: May 15, 2024
Language: Английский
Citations
35
Cell Reports, Journal Year: 2024, Volume and Issue: 43(8), P. 114520 - 114520
Published: July 17, 2024
Highlights•SLip, FLiRT, and KP.2 are poorly neutralized by bivalent-vaccinated sera•XBB.1.5-vaccinated hamster JN.1 patient sera SLip, KP.2•S mutations R346T, L455S, F456L alter ACE2 binding neutralization epitopes•SLip, spikes exhibit less fusion processing relative to JN.1SummaryWe investigate JN.1-derived subvariants for antibodies in vaccinated individuals, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients, or class III monoclonal antibody S309. Compared JN.1, KP.2, especially FLiRT increased resistance BA.2.86/JN.1-wave convalescent human sera. XBB.1.5 monovalent-vaccinated robustly neutralize but have reduced efficiency SLip. All resistant S309 show decreased infectivity, cell-cell fusion, spike JN.1. Modeling reveals that L455S SLip reduce ACE2, while R346T strengthens it. These three mutations, alongside D339H, key epitopes spike, likely explaining the sensitivity of these neutralization. Our findings highlight suggest future vaccine formulations should consider as an immunogen, although current monovalent could still offer adequate protection.Graphical abstract
Language: Английский
Citations
33
Eurosurveillance, Journal Year: 2024, Volume and Issue: 29(10)
Published: March 7, 2024
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and January 2024 in 23,895 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) 18–59-year-olds 50% 44–56) 60–85-year-olds. Sequencing data suggest lower protection the BA.2.86 (including JN.1) variant from recent prior (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, 1.5; CI:0.8–2.6).
Language: Английский
Citations
32
bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown
Published: April 22, 2024
Abstract The continuous evolution of SARS-CoV-2, particularly the emergence BA.2.86/JN.1 lineage replacing XBB lineages, necessitates re-evaluation current vaccine compositions. Here, we provide a comprehensive analysis humoral immune response to and JN.1 human exposures, emphasizing need for JN.1-lineage-based boosters. We demonstrate antigenic distinctiveness lineages in SARS-CoV-2-naive individuals but not those with prior vaccinations or infections, infection elicits superior plasma neutralization titers against its subvariants. highlight strong evasion receptor binding capability KP.3, supporting foreseeable prevalence. Extensive BCR repertoire, isolating ∼2000 RBD-specific monoclonal antibodies (mAbs) their targeting epitopes characterized by deep mutational scanning (DMS), underscores systematic superiority JN.1-elicited memory B cells (MBCs). Notably, Class 1 IGHV3-53/3-66-derived neutralizing (NAbs) contribute majorly within wildtype (WT)-reactive NAbs JN.1. However, KP.2 KP.3 evade substantial subset them, even induced JN.1, advocating booster updates optimized enrichment. JN.1-induced Omicron-specific also high potency across all Omicron lineages. Escape hotspots these have mainly been mutated RBD, resulting higher barrier escape, considering probable recovery previously escaped NAbs. Additionally, prevalence broadly reactive IGHV3-53/3-66- encoding MBCs, competing suggests inhibitory role on de novo activation naive cells, potentially explaining heavy imprinting mRNA-vaccinated individuals. These findings delineate evolving antibody shift from importance developing lineage, especially KP.3-based boosters, enhance immunity future SARS-CoV-2 variants.
Language: Английский
Citations
20